Mirtazapin Ct (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Ct, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Ct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Mirtazapine is used in the treatment of depressive disorders, acting primarily on neurotransmitter pathways associated with mood regulation.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Treatment‑resistant depression: may be considered as an alternative when first‑line agents are ineffective.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction - Seizures - Suicidal thoughts or behavior - Serotonin syndrome when combined with other serotonergic agents

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

- Monitor weight: patients often experience increased appetite and weight gain. - Assess liver function: use caution in patients with hepatic impairment. - Evaluate for suicidal ideation: especially during early treatment. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Use caution in the elderly: increased sensitivity to sedation and orthostatic hypotension. - Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Antihistamines: may enhance sedative effects.